Arlington Capital Partners Acquires a Majority Interest in Riverpoint Medical

Arlington Capital Partners has completed a majority growth investment in Riverpoint Medical. The investment in Riverpoint marks the first deal out of Arlington’s $1.7 billion Fund V. Riverpoint Medical is a developer, designer, and manufacturer of medical devices focused on advanced bio-medical textile technologies. The company has a history of product innovation and intellectual property development across bioabsorbable sutures, high strength medical fiber and suture-based implantable devices. Riverpoint’s advanced polymer technologies address the demands of large and rapidly growing global markets including wound closure, sports medicine, animal health and regenerative medicine.
 
Matt Altman, a managing partner at Arlington, said, “Arlington is thrilled to partner with the Riverpoint team to continue building a manufacturer of advanced textile-based medical devices. Riverpoint’s ability to develop technologies coupled with its manufacturing processes provide a strong platform to accelerate growth in large addressable markets. Our investment in Riverpoint continues Arlington’s history of building differentiated, high-growth medical device manufacturers in partnership with company founders and existing senior management.”
 
Pat Ferguson, CEO of Riverpoint, stated, “We chose to partner with Arlington because of its long track record of success investing in, and scaling, medical device manufacturers. We are extremely pleased to work together with Arlington to take Riverpoint to the next level of growth as Arlington shares our vision for expanding Riverpoint’s capabilities to better serve our customers and employees. Arlington’s ability to provide significant strategic and capital support is differentiated and will further enable Riverpoint to expand our offerings to our clients, increase our manufacturing capacity, and most importantly, help enhance surgical outcomes.”
 
Gordon Auduong, a vice president of Arlington, added, “We have been very impressed with the company’s ability to capitalize on the growth trends in the sports medicine and animal health markets. We believe that Arlington can provide the strategic support and investments necessary to accelerate this exciting platform. We look forward to partnering with Riverpoint management team to propel the company through its next phase of growth.”
 
Riverpoint’s founders and senior management have all made substantial investments as part of the transaction and will continue to lead the company’s strategic growth initiatives in the future. The Walden Group served as advisor to the company on the transaction.
 
Arlington Capital Partners is a Washington, D.C.-based private equity firm that is currently investing out of Arlington Capital Partners V L.P., a $1.7 billion fund. The firm has managed approximately $4 billion of committed capital via five investment funds. Arlington is focused on middle-market investment opportunities in growth industries including healthcare, government services and technology, aerospace & defense, and business services and software. The firm’s professionals and network have a combination of operating and private equity experience that enable Arlington to be a value-added investor. Arlington invests in companies in partnership with management teams that establish and/or advance their company’s position as leading competitors in their field.
 
Headquartered in Portland, Ore., Riverpoint Medical is a developer, designer, and manufacturer of medical devices focused on advanced bio-medical textile technologies. Riverpoint’s wound closure products include a portfolio of bio-absorbable and non-absorbable sutures for the surgical and animal health markets. The company’s sports medicine offering includes implants and high strength fiber solutions utilizing its proprietary ultra-high molecular weight polyethylene (UHMWPE) non-absorbable suture (HS Fiber). Additionally, Riverpoint is a provider of cordless LED surgical headlights (MedLED) and offers a suite of brachytherapy products for the oncology market.